The Danish Health and Medicines Authority wants a targeted and relevant process for collecting additional information to reports on adverse drug reactions.
Therefore, we are by 15 December 2014 implementing a new procedure to ensure, that the information requested as follow up will in fact contribute significantly to the scientific evaluation of the case.
The new procedure is based on well-defined criteria for selection of cases relevant for follow up.